# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lowers the price target from ...
Molecular Partners (NASDAQ:MOLN) Q2 EPS $(0.67) Down from $(0.56) YoY
In H1 2025, Molecular Partners undertook a strategic review of its operations and headcount, with the objectives of increased e...